In the first part of this comprehensive review of thrombolytic therapy in clinical medicine, we begin with a brief history of fibrinolysis, followed by a review of the components of die endogenous fibrinolytic system and the currently available plasminogen activators. An in-depth examination of thrombolysis in treatment of acute myocardial infarction follows, Including recommendations for management based on available clinical trial data. New developments in thrombolytic therapy are also discussed.
Get full access to this article
View all access options for this article.
References
1.
SmithJARossWD. Translation of Aristotle's de partibus animalium. Oxford: Clarendon Press, 1912: Book 11:4
2.
HunterJ. Treatise on blood, inflammation, and gunshot wounds. London: G. Nicoll, 1794: 575
3.
DastreA. Fibrinolyse dans le sang. Arch Phys Normale Pathol1893: 5:661
4.
TilletWSGarnerRL. The fibrinolytic activity of hemolytic streptococci. J Exp Med1933; 58:485
5.
ChristensenLRMacLeodCM. A proteolytic enzyme of serum: Characterization, activation and reaction with inhibitors. J Gen Physiol1945; 28:559
6.
MacfarlaneRGPillingJ. Observations on fibrinolysis: Plasminogen, plasmin and antiplasmin content of human blood. Lancet1946; 11:562–565
7.
AstrupTPerminPM. Fibrinolysis in the animal organism. Nature1947: 159:681
8.
TilletWSSherryS. The effect in patients of streptococcal fibrinolysis (streptokinase) and streptococcal desoxyribonuclease on fibrinous, purulent and sanguinous pleural exudations. J Clin Invest1949; 28:173–190
9.
FletcherAPAlkjaersigNSherryS. The maintenance of a sustained thrombolytic state in man. J Clin Invest1959; 38:1096–1119
10.
JohnsonAJMcCartyWR. The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. J Clin Invest1959; 38:1627–1643
11.
SharmaGVRK. Historical overview of antithrombotic and thrombolytic therapy. Am J Med1987; 83(suppl 2): 2S–5S
12.
DalenJ. The case against fibrinolytic therapy. J Cardiovasc Med1980; 5:799–806
13.
DeWoodMASporesJNotskeR. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N. Engl J Med1980; 303:897–902
14.
KennedyJW. Streptokinase for the treatment of acute myocardial infarction: A brief review of randomized trials. J Am Coll Cardiol1987; 10:28B–32B
15.
HenkinJMarcottePYangH. The plasminogen-plasmin system. Prog Cardiovasc Dis1991; 34:135–164
16.
RobbinsKC. The plasminogen-plasmin enzyme system. In: ColmanRWHirshJMarderVJSalzmanEW, eds. Hemostasis and thrombosis: Basic principles and clinical practice. Philadelphia: JB Lippincott, 1987: 340–357
17.
FrancisCWMarderVJ. Physiologic regulation and pathologic disorders of fibrinolysis. In: ColmanRWHirshJMarderJVSalzmanEW, eds. Hemostasis and thrombosis: Basic principles and clinical practice. Philadelphia: JB Lippincott, 1987: 358–379
18.
KesslerCM. Anticoagulation and thrombolytic therapy: Practical considerations. Chest1989; 95(suppl): 245S–256S
HarpelPC. Human alpha2-macroglublin. In: LorandL, ed. Methods in enzymology. New York: Academic Press, 1976
21.
AokiNMoroiMTachiyaK. Effects of alpha2-plasmin inhibitor on fibrin clot lysis: Its comparison with alpha2-macro-globulin. Thromb Haemost1978; 39:22–31
22.
CrawfordGPMOgstonDDouglasAS. The contribution of plasma protease inhibitors to antiplasmin activity in man. Clin Sci Mol Med1976; 51:215
23.
GoaKLHenwoodJMStolzJF. Intravenous streptokinase: A reappraisal of its therapeutic use in myocardial infarction. Drugs1990; 39:693–719
24.
McClintockDKBellPH. The mechanism of activation of human plasminogen by streptokinase. Biochem Biophys Res Commun1971; 43:694
25.
FearsR. The effect of heparin and fibrin on the enzymatic efficiencies of thrombolytics in vitro. Drugs1987; 33(suppl 3): 69–74
26.
ArntzRHeitzJSchäferHSchröderR. Hemorrheology in acute myocardial infarction: Effects of high-dose intravenous streptokinase. Circulation1985; 72(suppl III): 417
27.
WilliamsJRB. The fibrinolytic activity of the urine. Br J Exp Pathol1951; 32:530
28.
LoscalzoJ. An overview of thrombolytic agents. Chest1990; 97(suppl): 117S–123S
29.
ThorsenSGlas-GreenwaltPAstrupT. Differences in the binding to fibrin of urokinase and tissue plasminogen activator. Thromb Diath Haemorrh1972; 28:65
30.
RobbinsKCSummariaLHsiehBShahRJ. The peptide chains of human plasmin: Mechanism of activation of human plasminogen to plasmin. J Biol Chem1967; 242:2333
31.
Urokinase Pulmonary Embolism Trial.Phase I results: A cooperative study. JAMA1970; 214:2163
32.
BachmannF. Plasminogen activators. In: ColmanRWHirshJMarderVJSalzmanEW, eds. Hemostasis and thrombosis: Basic principles and clinical practice. Philadelphia: JB Lippincott, 1987: 318–339
33.
MarderVJBellWR. Fibrinolytic therapy. In: ColmanRWHirshJMarderVJSalzmanEW, eds. Hemostasis and thrombosis: Basic principles and clinical practice. Philadelphia: JB Lippincott, 1987: 1393–1437
MungerMAForrenceEA. Anistreplase: A new thrombolytic for the treatment of acute myocardial infarction. Clin Pharm1990; 9:530–540
36.
HussainSSGurewichVLipinskiB. Purification of a new, high molecule weight form of urokinase from urine (abstract). Thromb Haemost1981; 46:11
37.
GurewichVPannellRLovieS. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J Clin Invest1984; 73:1731–1739
38.
Van de WerfFNobuharaMCollenD. Coronary thrombolysis with human single-chain urokinase type plasminogen activator (pro-urokinase) in patients with myocardial infarction. Ann Intern Med1986; 104:345–348
39.
StumpDCThienpontMCollenDC. Urokinase-related proteins in human urine. Isolation and charcterization of single-chain urokinase (prourokinase) and urokinase-inhibitor complex. J Biol Chem1986; 261:1267–1273
40.
GurewichV. Physicochemical properties and promotion of its fibrinolytic activity by urokinase and by tissue plasminogen activator with which it has a complementary mechanism of action. Semin Thromb Hemost1988; 14:110–115
41.
LijnenHRStumpDCCollenDC. Single-chain urokinase type plasminogen activator: Mechanism of action and thrombolytic properties. Semin Thromb Hemost1987; 13:152–159
42.
LarsenGRTimonyGAHorganPG. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase. J Biol Chem1991; 266:8156–8161
43.
JacksonCVCroweVGCraftTJ. Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis. Circulation1990; 82:930–940
44.
AhernTJMorrisGEBaroneKM. Site-directed mutagenesis in human tissue-plasminogen activator. J Biol Chem1990; 265:5540–5545
45.
MadisonELGoldsmithEJGerardRD. Serpin-resistant mutants of human tissue-type plasminogen activator. Nature1989; 339:721–724
46.
CollenDLijnenHR. New thrombolytic agents. Prog Cardiol1990; 3:29–43
47.
CollenDStassenJMStumpDCVerstraeteM. Synergism of thrombolytic agents in vivo. Circulation1986; 74:838–842
48.
GurewichVPannellR. A comparative study of the efficacy and specificity of tissue plasminogen activator and prourokinase: Demonstration of synergism and of different thresholds of non-selectivity. Thromb Res1986; 44:217–228
49.
SpriggsDJStassenJMHashimotoYCollenD. Thrombolytic properties of human tissue type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combintions in venous thrombosis models in dogs and rabbits. Blood1989; 73:1207–1211
50.
BodeCSchönermarkSSchulerG. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator (scuPA) and recombinant tissue-type plasminogen activator (rtPA) in acute myocardial infarction. Clin Res1989; 37:247A
51.
CaliffRMTopolEJStackRS. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction: Results of thrombolysis and angioplasty in myocardial infarction—phase 5 randomized trial. Circulation1991; 83:1543–1556
LijnenHRCollenD. Toward the development of improved thrombolytic agents. Br J Haematol1991; 77:261–266
54.
GardellSJRamjitDRStabilitoII. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbit. Circulation1991; 84:244–253
55.
RaoAKPrattCBerkeA. Thrombolysis in myocardial infarction (TIMI) trial-phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol1988; 11:1–11
56.
GimpleLWGoldHKLeinbachRC. Correlation between template bleeding times and spontaneous bleeding during treatment with recombinant tissue type plasminogen activator. Circulation1989; 80:581–588
57.
EisenbergPRJaffeASStumpDC. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis. Circulation1990; 82:1154–1168
58.
BellWRPitneyWRGoodwinJF. Therapeutic defibrination in the treatment of thrombotic disease. Lancet1968; 1:490–493
59.
RentropPBlankeHKosteringK. Acute myocardial infarction intracoronary application of nitroglycerin and streptokinase in combination with transluminal recanalization. Clin Cardiol1979; 5:354–363
60.
MarderVJFrancisCW. A assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis. Prog Hemost Thromb1984; 7:325–356
61.
KennedyJWRitchieJLDavisKBFritzJK. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med1983; 309:1477–1482
62.
SimoonsMLVan der BrandMde ZwaanC. Improved survival after early thrombolysis in acute myocardial infarction. Lancet1985; 2:578–581
63.
KennedyJWRitchieJLDavisKB. Western Washington intracoronary streptokinase trial follow-up. N Engl J Med1985; 312:1073–1078
64.
Groppo Italiano Per Lo Studio Delia Streptochinasi Nell'Infarto Miocardico (GISSI).Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet1986; 1:397–402
65.
Second International Study of Infarct Survival (ISIS-2) Collaborative Group.Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction. Lancet1988; 2:349–360
66.
CollenDCGoldHK. New developments in thrombolytic therapy. Thromb Res1990; (suppl 10): 105–131
67.
WilcoxRG. Thrombolysis with tissue plasminogen activator in suspected myocardial infarction: The ASSET study. Chest1989; 95(suppl): 270S–275S
68.
TimmsADGriffinBCrickJCPSowtonE. Anisolyated plasminogen streptokinase activator complex in acute myocardial infarctions: A placebo-controlled arteriographic coronary recanalization study. J Am Coll Cardiol1987; 10:205–210
69.
AIMS trial study group.Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet1988; 1:545–549
70.
MatheyDGSchoferJSheehanFH. Intravenous urokinase in acute myocaridal infarction. Am J Cardiol1985; 55:878–882
71.
NeuhausKLTebbeUGottwikM. Intravenous recombinant tissue plasminogen activator and urokinase in acute myocardial infarction: Results of the German activator urokinase study (GAUS). J Am Coll Cardiol1988; 12:581–587
72.
WallTCPhillipsHRStackRS. Results of high dose intravenous urokinase for acute myocardial infarction. Am J Cardiol1990; 65:124–131
73.
DiefenbachCErbelRPopT. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction. Am J Cardiol1988; 61:966–970
74.
LoscalzoJWhartonTPKirshenbaumJM. Clot selective coronary thrombolysis with pro-urokinase. Circulation1989; 79:776–782
75.
KasperWHohnloserSHEnglerH. Coronary reperfusion studies with pro-urokinase in acute myocardial infarction: Evidence for synergism of low dose urokinase. J Am Coll Cardiol1990; 16:773–738
76.
VerstraeteMBernardRBoryM. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet1985; 1:842–847
77.
ChesebroJHKnatterudGRobertsR. Thrombolysis in myocardial infarction (TIMI) trial phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation1987; 76:142–154
78.
WhiteHDRiversJTMaslowskiAH. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med1989; 320:817–821
79.
Magnani B, for the PAIMS Investigators. Plasminogen-activator-Italian multicenter study (PAIMS): Comparison of intravenous recombinant single-chain human tissue-type plasminogen activator with intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol1981; 13:19–26
80.
BonnierHJRMVisserRFKlompsHC. Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction. Am J Cardiol1988; 62:25–30
81.
AndersonJLRothbardRLHackworthyRA. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: Controlled comparison with intracoronary streptokinase. J Am Coll Cardiol1988; 11:1153–1163
82.
BrochierMLQuilletLKolbertusH. Intravenous anisoylated plasminogen streptokinase activator complex versus intravenous streptokinase in evolving myocardial infarction: Preliminary data from a randomized multicenter study. Drugs1987; (suppl 3): 140–145
83.
AndersonJLSorensonSGMorenoFL. Multicenter patency trial of intravenous anistreplase compared with streptokinase in acute myocardial infarction. Circulation1991; 83:126–140
84.
PRIMI trial study group. Randomized double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet1989; 1:863–868
85.
Gruppo Italiano per lo Studio della Soprawivenza nell' Infarto Miocardico.GISSI-2: A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet1990; 336:65–71
86.
The Interntional Study Group.In-hospital mortality and clinical cause of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and Streptokinase with or without heparin. Lancet1990; 336:71–75
87.
ISIS Collaborative Group.International study of infarct survival (ISIS)-3: Preliminary results. ISIS press release 1991: 1–31
88.
BleichSDNicholsTCSchumacherRR. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol1990; 66:1412–1417
89.
CrossDBAshtonNGNorrisRMWhiteHD. Comparison of the effects of streptokinase and tissue plasminogen activator on regional wall motion after first myocardial infarction: Analysis by the center line method with correction for area at risk. J Am Coll Cardiol1991; 17:1039–1046
90.
AgnelliG. Rationale for bolus t-PA therapy to improve efficacy and safety. Chest1990; 97(suppl): 161S–167S
91.
AgnelliGBuchananMRFernandezF. Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits. Blood1985; 66:399–401
92.
ClozelJPTschoppTLuedinEHoluoetP. Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model. Circulation1989; 79:125–133
93.
AgnelliGBuchananMRFernandezFHirshJ. The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: Influence of dosage regimens in rabbits. Thromb Res1985; 40:764–777
94.
TranchesiBVerstraeteMVanhoveP. Intravenous bolus administration of recombinant tissue plasminogen activator to patients with acute myocardial infarction. Coronary Artery Disease1990; 1:83–88
95.
TranchesiBChamoneDFCobbaertC. Coronary recanalization rate after intravenous bolus of alteplase in acute myocardial infarction. Am J Cardiol1991; 68:161–165
96.
NeuhausKLFeuererWJeep-TebbeS. J Am Coll Cardiol1989; 14:1566–1569
CaliffRMTopolEJStackRS. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction: Results of the TAMI-5 randomized trial. Circulation1991; 83:1543–1556
99.
The Urokinase and Alteplase in Myocardial Infarction Collaborative Group.Combination of urokinase and alteplase in the treatment of myocardial infarction. Coronary Artery Disease1991; 2:225–235
100.
YasudaTGoldHKLeinbachRC. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody. J Am Coll Cardiol1990; 16:1728–1735
101.
SarembockIJGertzSDGimpleLW. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation1991; 84:232–243
102.
YasudaTGoldHKYaoitaH. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet GPIIIb/IIIa antibody, on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine population. J Am Coll Cardiol1990; 16:714–722
103.
GoreJMSloanMPriceTR. Intracerebral hemorrhage, cerebral infarction and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study. Circulation1991; 83:448–459
104.
FitzgeraldDJCatellaFRoyLFitzGeraldGA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation1988; 77:142–150
105.
OhlsteinEHStorerBFujitaTShebuskiRJ. Tissue-type plasminogen activator and streptokinase induce platelet hyperaggregability in the rabbit. Thromb Res1987; 46:575–585
106.
RuddMAGeorgeDAmaranteD. Temporal effects of thrombolytic agents on platelet function in vivo and their modulation by prostaglandins. Circ Res1990; 67:1175–1181
107.
SherryS. Appraisal of various thrombotic agents in the treatment of acute myocardial infarction. Am J Med1987; 83(suppl 2A): 31–46
108.
AndersonJL. Reperfusion, patency “and reocclusion with anistreplase (APSAC) in acute myocardial infarction. Am J Cardiol1989; 64:12A–17A
109.
van WelyRelik LVisserRFvan der PolJMJ. Angiographically assessed coronary arterial patency and reocclusion in patients with anistreplase: Results of the anistreplase reocclusion multicenter study (ARMS). Am J Cardiol1991; 68:296–300
110.
StumpDCCaliffRMTopolEJ. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator: Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. Circulation1989; 80:1222–1230
